BCYC · Bicycle Therapeutics plc American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BCYC by emailGet an email when BCYC pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BCYC, unsubscribe in one click. Privacy
📣 What BCYC Says Is Next
in 2027 · “We remain on track to begin the Phase 1 trial for BT1702, our MT1-MMP targeting BRC, in 2027, backed by compelling human imaging data validating the targeting precision and translatability of our Bicycle ® technology.” Dr Lee added: “It is an honor to welcome world-renowned oncologist Professor Thomas Powles to our Clinical Advisory Board.”
Company press release, Jul 30, 2026 · SEC filing
second half of 2026 · “The company plans to share additional Duravelo-2 data from the randomized Phase 2 trial in the second half of 2026.”
Company press release, May 21, 2026 · SEC filing
in 2027 · “Bicycle Therapeutics continues to advance its emerging radioligand pipeline, with additional EphA2 human imaging data expected in the first half of 2026 and the initiation of the first company-sponsored radioligand clinical trial, for BT1702, an MT1-MMP targeting BRC, expected in 2027. · BT5528, a potential first-in-class EphA2 targeting BDC molecule.”
Company press release, Mar 17, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BCYC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCYC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.